Investig Clin Urol.  2016 Jul;57(4):231-239. 10.4111/icu.2016.57.4.231.

Small renal masses in the elderly: Contemporary treatment approaches and comparative oncological outcomes of non-surgical and surgical strategies

• Vetterlein MW
• Jindal T
• Becker A
• Regier M
• Kluth LA
• Tilki D
• Chun FK

• KMID: 2426500
• DOI: http://doi.org/10.4111/icu.2016.57.4.231

Abstract

Over the last decades, there has been a significant stage migration in renal cell carcinoma and especially older patients are getting diagnosed more frequently with low stage disease, such as small renal masses ≤4 cm of size. Considering the particular risk profile of an older population, often presenting with a nonnegligible comorbidity profile and progressive renal dysfunction, treatment approaches beyond aggressive radical surgical procedures have come to the fore. We sought to give a contemporary overview of the available different treatment strategies for incidental small renal masses in an elderly population with the focus on comparative oncological outcomes of nonsurgical and surgical modalities.

Keyword

Ablation techniques; Aged; Kidney neoplasms; Nephrectomy; Watchful waiting

MeSH Terms

Ablation Techniques/methods
Carcinoma, Renal Cell/pathology/*therapy
Humans
Kidney Neoplasms/pathology/*therapy
Nephrectomy/*methods
Treatment Outcome
Watchful Waiting

Reference

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7–30.

2. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008; 113:78–83.

3. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006; 98:1331–1334.

4. King SC, Pollack LA, Li J, King JB, Master VA. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol. 2014; 191:1665–1670.

5. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003; 170(6 Pt 1):2217–2220.

6. Silver DA, Morash C, Brenner P, Campbell S, Russo P. Pathologic findings at the time of nephrectomy for renal mass. Ann Surg Oncol. 1997; 4:570–574.

7. Sun M, Becker A, Tian Z, Roghmann F, Abdollah F, Larouche A, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. 2014; 65:235–241.

8. Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson BT, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010; 116:3119–3126.

9. Tan HJ, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA. 2012; 307:1629–1635.

10. Yang G, Villalta JD, Meng MV, Whitson JM. Evolving practice patterns for the management of small renal masses in the USA. BJU Int. 2012; 110:1156–1161.

11. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004; 100:738–745.

12. Volpe A, Jewett MA. The role of surveillance for small renal masses. Nat Clin Pract Urol. 2007; 4:2–3.

13. Patel HD, Johnson MH, Pierorazio PM, Sozio SM, Sharma R, Iyoha E, et al. Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature. J Urol. 2016; 195:1340–1347.

14. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy--a renaissance? J Urol. 2008; 179:20–27.

15. Volpe A, Kachura JR, Geddie WR, Evans AJ, Gharajeh A, Saravanan A, et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol. 2007; 178:379–386.

16. Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol. 2016; 69:660–673.

17. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009; 182:1271–1279.

18. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015; 67:913–924.

19. Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR, et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol. 2011; 60:39–44.

20. Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012; 118:997–1006.

21. Mason RJ, Abdolell M, Trottier G, Pringle C, Lawen JG, Bell DG, et al. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol. 2011; 59:863–867.

22. Santos Arrontes D, Fernandez Acenero MJ, Garcia Gonzalez JI, Martin Munoz M, Paniagua Andres P. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol. 2008; 179:857–861.

23. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007; 109:1763–1768.

24. Berger DA, Megwalu II, Vlahiotis A, Radwan MH, Serrano MF, Humphrey PA, et al. Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma. Urology. 2008; 72:359–363.

25. Kutikov A, Egleston BL, Canter D, Smaldone MC, Wong YN, Uzzo RG. Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol. 2012; 188:2077–2083.

26. Danzig MR, Chang P, Wagner AA, Allaf ME, McKiernan JM, Pierorazio PM. Active surveillance for small renal masses: a review of the aims and preliminary results of the DISSRM registry. Curr Urol Rep. 2016; 17:4.

27. Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol. 2015; 68:408–415.

28. Becker A, Roghmann F, Ravi P, Tian Z, Kluth LA, Gandaglia G, et al. Delay in nephrectomy and cancer control outcomes in elderly patients with small renal masses. Urol Int. 2014; 92:455–461.

29. Meyer C, Hansen J, Becker A, Schmid M, Pradel L, Strini K, et al. The adoption of nephron-sparing surgery in Europe - a trend analysis in two referral centers from Austria and Germany. Urol Int. 2016; 96:330–336.

30. Bianchi M, Becker A, Abdollah F, Trinh QD, Hansen J, Tian Z, et al. Rates of open versus laparoscopic and partial versus radical nephrectomy for T1a renal cell carcinoma: a population-based evaluation. Int J Urol. 2013; 20:1064–1071.

31. Sun M, Abdollah F, Bianchi M, Trinh QD, Jeldres C, Thuret R, et al. Treatment management of small renal masses in the 21st century: a paradigm shift. Ann Surg Oncol. 2012; 19:2380–2387.

32. Patel HD, Mullins JK, Pierorazio PM, Jayram G, Cohen JE, Matlaga BR, et al. Trends in renal surgery: robotic technology is associated with increased use of partial nephrectomy. J Urol. 2013; 189:1229–1235.

33. Kardos SV, Gross CP, Shah ND, Schulam PG, Trinh QD, Smaldone MC, et al. Association of type of renal surgery and access to robotic technology for kidney cancer: results from a population-based cohort. BJU Int. 2014; 114:549–554.

34. Wu Z, Li M, Liu B, Cai C, Ye H, Lv C, et al. Robotic versus open partial nephrectomy: a systematic review and meta-analysis. PLoS One. 2014; 9:e94878.

35. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007; 51:1606–1615.

36. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors: is there a difference in mortality and cardiovascular outcomes? J Urol. 2009; 181:55–61.

37. Shiroki R, Fukami N, Fukaya K, Kusaka M, Natsume T, Ichihara T, et al. Robot-assisted partial nephrectomy: Superiority over laparoscopic partial nephrectomy. Int J Urol. 2015; 11. 20. [Epub]. DOI: 10.1111/iju.13001.

38. Zini L, Perrotte P, Jeldres C, Capitanio U, Duclos A, Jolivet-Tremblay M, et al. A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. BJU Int. 2009; 103:899–904.

39. Zastrow S, Phuong A, von Bar I, Novotny V, Hakenberg OW, Wirth MP. Primary tumor size in renal cell cancer in relation to the occurrence of synchronous metastatic disease. Urol Int. 2014; 92:462–467.

40. Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2010; 28:311–317.

41. Weight CJ, Larson BT, Fergany AF, Gao T, Lane BR, Campbell SC, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol. 2010; 183:1317–1323.

42. Takaki H, Soga N, Kanda H, Nakatsuka A, Uraki J, Fujimori M, et al. Radiofrequency ablation versus radical nephrectomy: clinical outcomes for stage T1b renal cell carcinoma. Radiology. 2014; 270:292–299.

43. Woldu SL, Thoreson GR, Okhunov Z, Ghandour R, Rothberg MB, RoyChoudhury A, et al. Comparison of renal parenchymal volume preservation between partial nephrectomy, cryoablation, and radiofrequency ablation using 3D volume measurements. J Endourol. 2015; 29:948–955.

44. Regier M, Chun F. Thermal ablation of renal tumors: indications, techniques and results. Dtsch Arztebl Int. 2015; 112:412–418.

45. Khiatani V, Dixon RG. Renal ablation update. Semin Intervent Radiol. 2014; 31:157–166.

46. Takaki H, Yamakado K, Soga N, Arima K, Nakatsuka A, Kashima M, et al. Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma. Jpn J Radiol. 2010; 28:460–468.

47. Olweny EO, Park SK, Tan YK, Best SL, Trimmer C, Cadeddu JA. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up. Eur Urol. 2012; 61:1156–1161.

48. Stern JM, Svatek R, Park S, Hermann M, Lotan Y, Sagalowsky AI, et al. Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours. BJU Int. 2007; 100:287–290.

49. Haber GP, Lee MC, Crouzet S, Kamoi K, Gill IS. Tumour in solitary kidney: laparoscopic partial nephrectomy vs laparoscopic cryoablation. BJU Int. 2012; 109:118–124.

50. Klatte T, Mauermann J, Heinz-Peer G, Waldert M, Weibl P, Klingler HC, et al. Perioperative, oncologic, and functional outcomes of laparoscopic renal cryoablation and open partial nephrectomy: a matched pair analysis. J Endourol. 2011; 25:991–997.

51. Facciorusso A, Di Maso M, Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Int J Hyperthermia. 2016; 32:339–344.

52. Guan W, Bai J, Liu J, Wang S, Zhuang Q, Ye Z, et al. Microwave ablation versus partial nephrectomy for small renal tumors: intermediate-term results. J Surg Oncol. 2012; 106:316–321.